Bristol-Myers Squibb CoLTS:0R1F +4.49%76 Net Margin % is 23.30% as of Mar. 2026, which is 64% above its 10-year median of 14.18. GuruFocus rates LTS:0R1F with a GF Score™ of 76/100 and a GF Value™ of $54.74 (Fairly Valued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 78.97% on this metric.
The historical rank and industry rank for Bristol-Myers Squibb Co's Net Margin % or its related term are showing as below:
LTS:0R1F'
s Net Margin % Range Over the Past 10 Years
Min: -21.2 Med: 14.18 Max: 22.94
Current: 15.01
LTS:0R1F's Net Margin % is ranked better than 78.97% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs LTS:0R1F: 15.01
Bristol-Myers Squibb Co (LTS:0R1F) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Bristol-Myers Squibb Co Net Margin % Related Terms
Bristol-Myers Squibb Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R1F vs PFE, GILD, AMGN: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (LTS:0R1F) has a Net Margin % of 23.30% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. This is 64% above median its historical median of 14.18. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #201 out of 956 companies in the Drug Manufacturers industry, placing it in the top 21%.
Is Bristol-Myers Squibb Co's Net Margin % too high?
Bristol-Myers Squibb Co's current Net Margin % of 23.30% is 64% above median its 10-year median of 14.18. The Drug Manufacturers industry median Net Margin % is 5.56. Bristol-Myers Squibb Co's value of 23.30% is 319.1% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #201 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bristol-Myers Squibb Co has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Net Margin % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #201 out of 956 companies for Net Margin %. This places Bristol-Myers Squibb Co in the top 21% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Bristol-Myers Squibb Co's value of 23.30% is 319.1% above this benchmark. While the company's 10-year median is 14.18 vs. the industry median of 5.56, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current Net Margin % of 23.30% is 319.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bristol-Myers Squibb Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current Net Margin % is 23.30%, which is 64% above median its own 10-year median of 14.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (LTS:0R1F) is currently considered Fairly Valued. The stock's GF Value™ is $54.74, compared to a current price of $57.05 — trading 4.2% above its estimated fair value. The current Net Margin % is 23.30%, which is 64% above median its 10-year median of 14.18 and 319.1% above the Drug Manufacturers industry median of 5.56. Bristol-Myers Squibb Co's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (LTS:0R1F), the current Net Margin % is 23.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (LTS:0R1F) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $57.05 is trading 4.2% above its estimated GF Value™ of $54.74.
GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.
Key valuation signals for LTS:0R1F:
Net Margin %: 23.30% (64% above median its 10-year median of 14.18)
GF Value™: $54.74 vs. price of $57.05 (4.2% above fair value)
Industry Position: 319.1% above the Drug Manufacturers median (#201 of 956)
No single metric tells the full story. See the LTS:0R1F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
76GF Score
Get the complete analysis for LTS:0R1F
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R1F has been successfully added to your 
